SMILE for natural killer/T-cell lymphoma: Analysis of safety and efficacy from the Asia Lymphoma Study Group

Blood

Volumn 120, Issue 15, 2012, Pages 2973-2980

  Kwong, Yok Lam ^a   Kim, Won Seog ^b   Lim, Soon Thye ^c   Kim, Seok Jin ^b   Tang, Tiffany ^c   Tse, Eric ^a   Leung, Anskar Y H ^a   Chim, Chor Sang ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b Samsung Medical Center   (South Korea)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER T CELL; NEPHROTOXICITY; NEUTROPENIA; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84867810745     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-431460     Document Type: Article

References (20)

1. Chan JK, Quintanilla-Martinez L, Ferry JA, et al. WHO Classification of Tumours of Haematopoeitic and Lymphoid Tissue. Lyon, France: International Agency for Research on Cancer; 2008:285-288.
2. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12): 2186-2194.
3. Ishida F, Kwong YL. Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol. 2010;3(5):593-602.
4. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995;76(11):2351- 2356.
5. Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5): 1016-1020. (Pubitemid 351997606)
6. Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol. 2003;78(2):163-167. (Pubitemid 37021959)
7. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999;93(6):1869-1874. (Pubitemid 29128488)
8. Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410-4416.
9. Chan WK, Au WY, Wong CY, et al. Metabolic activity measured by F-18 FDG PET in natural killercell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med. 2010;35(8):571-575.
10. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
11. Juweid ME, Stroobants S, Hoekstra OS, et al. Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571-578. (Pubitemid 350002965)
12. Chan A, Tang T, Ng T, et al. To SMILE or not: supportive care matters. J Clin Oncol. 2012;30(9):1015-1016.
13. Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27(35):6027-6032.
14. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103(1):216-221.
15. Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27(33):5594-5600.
16. Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killercell malignancies. Bone Marrow Transplant. 2009;44(11):709-714.
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
18. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612-618. (Pubitemid 46630424)
19. Jaccard A, Gachard N, Marin B, et al. GELA and GOELAMS Intergroup. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834-1839.
20. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243-249. (Pubitemid 38879864)